Yahoo Finance • 20 days ago
Galapagos NV Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein Focusing on accelerating... Full story
Yahoo Finance • 5 months ago
Galapagos NV Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Director to its Board of Director... Full story
Yahoo Finance • last year
Galapagos NV Transaction expected to close in the first quarter of 2024, subject to customary closing conditions Michele Manto, Galapagos’ Chief Commercial Officer, to join Alfasigma Mechelen, Belgium; 02 January 2024, 07:00 CET; Galapag... Full story
Yahoo Finance • last year
Galapagos NV First nine months 2023 key financials: Group revenues of €448.9 million Jyseleca® net sales of €82.1 million Cash and current financial investments of €3.8 billion at 30 September 2023 Full year 2023 net Jyseleca® sales gu... Full story
Yahoo Finance • 2 years ago
Galapagos NV Clear path forward for accelerated growth and value creation Reshape innovation model andbuild fit-for-purpose organizationin key strategic therapeutic areas: immunology and oncology Jyseleca®2022 net sales guidance further... Full story
Yahoo Finance • 3 years ago
Galapagos NV Mechelen, Belgium;29 August 2022, 22.01CET;regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation1, Galapagos received a... Full story